Humoral hypercalcemic factor antagonists modified at position 13

Details Humoral hypercalcemic factor antagonists modified at position 13 Humoral hypercalcemic factor antagonists modified at position 13

1990-06-28

1992-02-11

Doll, John

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

435 75, 530324, 530325, 514 12, 436501, 930290, 930DIG820, G01N 33567, C07K 710, A61K 3724

Patent

active

050875612

ABSTRACT:
The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.

REFERENCES:
patent: 4423037 (1983-12-01), Rosenblatt et al.
patent: 4771124 (1988-09-01), Rosenblatt et al.
Juppner et al., Biochemistry, vol. 29(30), pp. 6941-6946, (1990).apprxeq.Chem. Abs. 113(15), 126872f.
Coltreua et al., American Chemical Society, vol. 19, No. 18, pp. 4380-4384 (1980).
The Merck Manual, 11th ed., pp. 452-453, (1966).
Abou-Samra et al., J. Biol. Chem., vol. 265(1), pp. 58-62, (1990), Chem. Abs. 112(5), 30969w.
Newman et al., J. Biol. Chem., vol. 264(28), pp. 16359-16366, (1989), Chem. Abs., vol. 111(25), 225412w.
Chorev et al., Biochem. Sty., 29(6), pp. 1580-1586, (1990), Chem. Abs., vol. 113(3), 17971s.
Nutt et al., Endocrinology, vol. 127(1), pp. 491-493, (1990), Chem. Abs. 113(17), 145428g.

Affiliated with

Also associated with

Rating

Humoral hypercalcemic factor antagonists modified at position 13 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humoral hypercalcemic factor antagonists modified at position 13, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humoral hypercalcemic factor antagonists modified at position 13 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-781538